Lakewood-Amedex Biotherapeutics Inc.

LABT Nasdaq SEC CIK 2079272
Follow Lakewood-Amedex Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.5M +22.7% vs same quarter last year
EPS, diluted −$0.62 +82.1% vs same quarter last year
Operating cash flow −$1.3M −106.7% vs same quarter last year
Operating income −$1.5M +19.7% vs same quarter last year
Net income by quarter
−$539.6K
−$655.9K
−$1.9M
−$744.9K
−$923.3K
−$3.8M
−$1.5M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing